EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti¿tumor necrosis factor-¿ as first- or second-line biologic treatment among patients with ulcerative colitis Francesc Casellas; Ana Gutiérrez-Casbas; Cristina Rodríguez; Javier P. Gisbert; Sabino Riestra; Claudia Herrera de Guise; Isabel Vera-Mendoza; M. Pilar Martínez-Montiel; Sónia Bernardo; Isabel Medeiros; Jesús Aparicio; Ignacio Tagarro; Teresa Letosa Abián; Carmen Montoto; J. Fernando Muñoz;

Duodenal target sign Ana Laranjo; Maria Carvalho; Andreia Rei; Nuno Veloso;